Biobot Surgical Revenue and Competitors

At Biobot Surgical, our mission is to revolutionize the realm of robotic-assisted biopsy and treatment for prostate cancer. As the landscape for prostate cancer treatment evolves, we aren’t just riding this wave of change — we’re propelling it, ushering in a new era of excellence in prostate disease management. \n\nAt the forefront of these advances in the standard of care in prostate cancer management, we are poised to address the global unmet need for a precise approach to transperineal procedures — and make a monumental impact on the lives of patients. Our first- and best-in-class surgical robot iSR’obot Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), the US (FDA), Australia (TGA), and Singapore (HSA), and is being used in some of the most prestigious hospitals around the world. \n\nWe remain committed to advancing innovation in the field of robotic-assisted transperineal biopsy and treatment, and delivering the precision urologists require—and patients deserve.